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Abstract.  We analyzed the binding of fibronectin to 
integrin a5/31 in various cells; in some cells fibronectin 
bound with low affinity (e.g., K562 cells) whereas in 
others (e.g., CHO), it bound with high affinity (Kd ,~ 
100 nM) in an energy-dependent manner. We con- 
structed chimeras of the extracellular and transmem- 
brane domains of c~3  joined to the cytoplasmic do- 
mains of otsBl. The affinity state of these chimeras was 
assessed by binding of fibrinogen or the monoclonal 
antibody, PACl.  The cytoplasmic domains of 0~5/~ con- 
ferred an energy-dependent high affinity state on otnbB3 
in CliO but not K562 cells. Three additional tx cyto- 
plasmic domains (ix2, otv~, ot~B) conferred PAC1 bind- 
ing in CHO cells, while three others (otM, OiL, av) did 
not. In the high affinity ot chimeras, cotransfection 
with a truncated (~3A724) or mutated (~3(S752"-~P)) 83 
subunit abolished high affinity binding. Thus, both cy- 
toplasmic domains are required for energy-dependent, 
cell type-specific affinity modulation. In addition, mu- 
tations that disrupted a highly conserved o~ subunit 
GFFICR motif, resulted in high affinity binding of 
ligands to Otnb/~3. In contrast to the chimeras, the high 
affinity state of these mutants was independent of cel- 
lular metabolism, cell type, and the bulk of the ~  sub- 
unit cytoplasmic domain. Thus, integrin cytoplasmic 
domains mediate inside-out signaling. Furthermore,  ' 
the highly conserved GFFKR motif of the c~ Subunit 
cytoplasmic domain maintains the default low affinity 
state. 
C 
ELLS alter their adhesiveness  in response  to devel- 
opmental events or environmental cues. These adap- 
tations  are often mediated through integrins,  adhe- 
sion receptors composed of two transmembrane subunits, ct 
and B (43). Rapid changes in integrin function are critical in 
cell migration, cellular aggregation,  and leukocyte trans- 
migration during inflammation (2, 24, 31, 36, 43, 75, 86). 
A given integrin may also manifest varying adhesive compe- 
tence depending on its cellular environment (15, 25, 49, 62, 
94), or the state of differentiation of the cell (1, 15, 35, 66). 
Such variations in function may be due to changes in ligand- 
binding affinity as occurs with certain/~3 (7), B2 (4), and/~ 
(26) integrins. Changes in adhesive function may also occur 
without changes  in  ligand-binding  affinity. For  example, 
phorbol  esters  stimulate  the  o~s/3~-dependent adhesion  of 
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CHO ceils (20) to fibronectin (Fn) ~  with no change in Fn- 
binding  affinity. Similarly,  certain  /33  mutations  reduce 
Otnb/33-dependent stabilization of cell adhesion to fibrinogen 
(Fg)  without changing  intrinsic  Fg-binding  affinity  (97). 
Such affinity-independent changes in integrin  function are 
ascribed to "post receptor events" (20).  Nevertheless,  the 
host cell governs the capacity of solubilized ot2Bl to bind to 
immobilized ligands (49). This last result suggests that some 
cell type-specific differences in integrin function may be due 
to differences in ligand-binding affinity. 
anbl33 (platelet GPllb-KIa) is a prototype integrin for anal- 
ysis of changes  in integrin  affinity. As with all integrins, 
~Xnbi33 is a heterodimer of two Type I transmembrane pro- 
tein subunits  (43),  o~iroB3 is platelet-specific  (88),  and af- 
finity  state-specific  antibodies,  e.g.,  PAC1 (81), simplify 
analysis  of recombinant oLnb~3 in heterologous  cells  (67). 
Conformational changes in the extracellular domain of OtnbB~ 
regulate its affinity (67, 82).  Platelet agonists increase the 
affinity of Oel~3 (U~activation')  via cytoplasmic signaling path- 
ways. These pathways include heterotrimeric GTP-binding 
proteins, phospholipid metabolism, and serine-threonine ki- 
nases and may also involve calcium fluxes, tyrosine kinases, 
1. Abbreviations  used in this paper: Fg, fibrinogen; Fn, fibronectin. 
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79, 80, 82). How cytoplasmic signals result in changes in the 
conformation and ligand-binding affinity of the extracellular 
domain ("inside-out signal transduction")  of the integrin re- 
mains obscure. 
A variety of in vitro treatments may alter integrin affinity. 
When  purified  O~nb/33 is  pretreated  with  RGD peptides,  it 
subsequently  binds  Fg  and  PAC1 (23,  50,  85).  Certain 
anti-/33 antibodies  directly  increase the Fg-binding affinity 
of Otnb~3 (29) and certain anti-fit  antibodies activate asBt to 
bind Fn with high affinity (26). Changes in the divalent cat- 
ion  composition  of the  extracellular  medium,  proteolytic 
digestion, and treatment with reducing agents may also "acti- 
vate" integrins (3, 30, 34, 48, 62, 94, 98). Thus, moieties that 
interact with the extracellular domain can modulate integrin 
affinity.  Furthermore,  lipid environment can alter an inte- 
grin's  ligand-binding  capacity  07,  85)  and  an  apparently 
novel lipid, IMF-1, may regulate o~M/32 (37). Although many 
treatments may change integrin affinity in vitro, the mecha- 
nism(s) of physiological modulation has not been defined. 
Integrin cytoplasmic domains may be targets of cytoplas- 
mic signals that alter integrin affinity. The cytoplasmic tails 
are ,~180 A from the ligand-binding site (93), but integrins 
can undergo propagated long-range conformational changes 
in situ (22). Truncation of the ott~ cytoplasmic domain after 
residue  990  (~nbA991)  results  in  otnb/~3 that  constitutively 
binds Fg and PAC1 (69). Conversely, truncations of or4 (45), 
or2 (46), and/~2 (39) profoundly reduce the capacity of these 
integrins to mediate cell adhesion, possibly due to effects on 
ligand-binding affinity.  Such truncations may result in mis- 
folded receptors that lack function or that bind ligands with 
an  inappropriately  high  affinity.  Furthermore,  a  Ser  752 to 
Pro mutation in the #3 cytoplasmic domain was associated 
with an apparent o~/33 activation defect (16) in a single in- 
dividual. Cytoplasmic domains of several integrins are phos- 
phorylated coincidentally  with increases in adhesive func- 
tion. Nevertheless, detailed studies (38, 40) have so far failed 
to establish a role for these phosphorylations in increased 
affinity. Conversely, the rounding of cells during mitosis is 
associated with phosphorylation of fit and reduced binding 
of ots/3t to Fn (43).  Thus,  physiological  activation  signals 
may be transmitted through integrin cytoplasmic domains, 
but definitive proof is lacking. 
In the present work, we tested the hypothesis that integrin 
cytoplasmic domains are directly involved in physiological 
affinity modulation. Using chimeras containing the cytoplas- 
mic domains of various a and/~ subunits joined to the trans- 
membrane and extracellular domain of o~3,  we found that 
integrin  cytoplasmic  domains  transduce  cell type-specific 
signals that modulate ligand-binding affinity.  These signals 
require active cellular processes and both ot and/~ cytoplas- 
mic tails of the integrin, suggesting that they represent phys- 
iologically relevant signals. In addition, deletion of a highly 
conserved  GFFKR  motif,  at the  NH2  terminus  of the  ot 
subunit cytoplasmic  domain,  also resulted in high affinity 
binding  of ligands  to  otm~3. In  contrast to the chimeras, 
high affinity ligand binding to GFFKR deletion mutants was 
independent of cellular metabolism, cell type, and the bulk 
of the/3 subunit cytoplasmic domain. Thus integrin cytoplas- 
mic tails are targets  for the modulation of integrin affinity. 
Materials and Methods 
Antibodies and Reagents 
The anti-cmbB3  antibody D57 was produced  by Dr. Xiaoping Du (Scripps 
Research  Institute) using previously described methods (28).  It binds to 
CHO ceils  transfected with ~nb~3 but not O~v~3, and does not block Fg 
binding to Otnb~3. This antibody was biotinylated with biotin-N-hydroxy- 
succiuimide (Sigma Chem. Co.,  St.  Louis,  MO) according  to manufac- 
turers directions.  The C~nb/33 complex specific  antibody,  2(312 (71), was 
supplied  by Dr.  Vhgil Woods (University of California, San Diego)  and 
used as dilutions of ascites fluid.  The anti-hamster a5 (PB1) and anti-/~t 
(7E2) antibodies were obtained from Dr. Rudolph Juliano (10) (University 
of North Carolina, Chapel Hill), and the/~t activating antibody, 8A2, was 
supplied by Drs. Nick Kovach and John Harlan (51) (University  of Washing- 
ton, Seattle). A human anti-c5 antibody, BIIG2, was supplied by Dr. Caro- 
line Damsky (95) (University of California, San Francisco) while a poly- 
clonal anti-peptide antibody against the cytoplasmic  domain of human ~5 
(44) was obtained from Drs. Gene Marcantonio and Richard Hynes (Mas- 
sachusetts Institute of Technology, Boston). The isolation and characteriza- 
tion of other antibodies  (anti-LIBS6,  anti-LIBS2, anti-c~wo cytoplasmic 
domain [28, 69]) and PAC1 (81) have been described. Glucose and 2-deoxy- 
glucose were purchased from Sigma and sodium azide was from Fisher Sci- 
entific  Co.  (Pittsburgh,  PA).  The peptide GRGDSP was  obtained from 
Peninsula Laboratories (Belmont, CA).  Its purity and composition were 
verified by high performance liquid chromatography and fast atom bom- 
bardment mass spectroscopy. 
Cell Culture and Transfection 
The human cell lines K562,  U937, WI38, and MG63 were obtained from 
the Amer.  Type  Culture Collection (Rockville,  MD) and maintained in 
RPMI 1640 media (Biowhittaker, Walkersville, MD) containing 10% FBS 
(Biowhittaker),  1% glutamine (Sigma), and 1% penicillin and streptomycin 
(Sigma). THlXl cells (Amer. Type Culture CoUection) were maintained in 
the same medium with the addition of 10 mM Hepes and 20 mM 2-mercap- 
toethanol. CHO cells (Amer. Type Culture Collection) were maintained in 
DMEM media (Biowhittaker)  with 10% FCS, the above noted antibiotics, 
and 1% non-essential amino acids (Sigma).  Human T lymphocytes  were 
purified from peripheral blood of normal donors by centrifngation on a 
Ficoll-Paque  gradient (Pharmacia Fine Chemicals, Piscataway, NJ), pan- 
ning for monocytes on serum-coated dishes, and passage over a nylon wool 
column. 
CHO cells were transiently transfected  by electroporation.  Cells in log 
phase growth were harvested with trypsin (Irvine Scientific),  washed with 
PBS,  and combined with appropriate cDNAs (10 ttg each subunit).  3  x 
107 cells in 0.5 ml in growth media were electroporated  at 350 V, 960/~F 
in a BTX (BTX, San Diego, CA) ciectroporator.  Media were changed after 
24 h, and cells analyzed for surface expression or PAC1 binding aRer 48 
h. Stable CHO transfectants were established as above with cotransfeetion 
of 0.6/~g of CDNeo.  After 48 h, these cells were selected for 2 wk in 700 
/~g/ml G418 (GIBCO BRL, Gaithershnrg, MD) and clonal lines were estab- 
lished by single cell sorting in a FACStar (Becton Dickinson Immunocytom- 
etry Sys., Mountain View, CA). Stable K562 transfectants were established 
by electroporafion  of 107 cells in 0.8 ml of PBS at 300 V and 500/~F. After 
48 h, the cells were maintained in media containing 1 mg/ml O418, and 
clonal lines established by limiting dilution cloning. 
Flow Cytometry 
Surface  expression of integrins was  analyzed by  flow  cytometry  with 
specific antibodies as described (57, 68).  Briefly, 5  x  105 cells were in- 
cuhated on ice for 30 rain with primary antibody,  washed,  and then in- 
cuhated on ice for 30 rain with an FITC-conjugated  goat anti-mouse ('lhgo, 
Buriingame,  CA) second antibody. Cells were pelleted, resuspended, and 
analyzed on a FACScan (Becton Dickinson Immunocytometry Sys.). PAC1 
binding was analyzed by two color flow cytometry. Cell staining was carried 
out in Tyrode's  (33)  buffer  containing 2  mM MgCIz and CaCI2 and  1 
mg/rrd BSA (Sigma) and dextrose.  Single cell suspensions  were obtained 
by harvesting with 3.5 mM EDTA, incubating for 5 rain in 1 mg/mi TPCK 
trypsin (Worthington)  and diluting with an equal volume of Tyrode's con- 
taining 10% FCS and 0.1% soybean trypsin inhibitor (Sigma).  After wash- 
ing,  5  ×  105 cells were incubated in a final volume of 50 t~l containing 
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After a 30-rain incubation at room temperature, cells were washed with cold 
Tyrode's solution and then incubated on ice with biotinylated antibody D57. 
After 30 m/n, cells were washed and then incubated on ice with Tyrode's 
containing 10%  F1TC-conjugated goat anti-mouse IgM  (Tago)  and 4% 
phyeoerythrin-streptavidin (Molecular Probos Inc., Junction City,  OR). 
Thirty minutes later cells were diluted to 0.5 mi with Tyrode's solution and 
analyzed on a FACScan (B¢cton Dickinson) flow cytometer as described 
(67). PAC1 binding (FITC staining) was analyzed only on a gated subset 
of ceils positive for an~3 expression (phycoerythrin staining). To define 
affinity state, histograms depietiog PAC1 staining in the absence or presence 
of 1 mM GRGDSP were supo'imposed. Since RGD peptides are inhibitors 
of PAC1 binding to am,/~3 (8), a rightward shift in the histogram in the ab- 
sence of peptide is indicative of the presence of high affinity c~,~3. To 
compare the effects of multiple a subunits, pooling of data involving experi- 
ments from different days, was required. To do this, a numerical activation 
index was defined as: 
100*(F0-FR)/FR where: 
Fo  =  Mean Fluorescence Intensity in the absence of inhibitor 
FR =  Mean Fluorescence Intensity in the presence of GRGDSP 
Expression of am/~3 in transiently transfected K562 cells was too low to 
permit affinity state analysis. Thus, all data reported with these cells is from 
stable lines. The truncation mutant, am,A991,  like a similar aL truncation 
(39), was expressed at low levels in transient transfections, so that all data 
obtained with this mutant refer to stable call lines. In contrast the aLA 
variant was well expressed, so that data from both transient and stable ex- 
periments are reported. Stable cell lines were also prepared with the follow- 
ing cytoplasmic domain combinations anb/~3, ~s/~3, cts/~sA724, a~3,  and 
ot~3A728.  The data with the stable cell lines confirmed the findings in 
transient analyses. All other combinations were tested in transient transfee- 
tions only. 
DNA Constructs 
The generation of CDM8 constructs encoding am,, a,m,A991, alr~A996,/33, 
and ~3A728 have been previously described (68,  69, 97). The B3 trunca- 
tion, A724,  and amino acid substitution, $752~P,  were first generated in 
BS3a  (68)  by oligonucleotide-direeted mutagenesis  (52),  digested with 
HincII to isolate coding sequences, ligated to BstXI linkers, flnvitrogen, 
San Diego, CA) and subcloned into the BstXI sites of CDMS. The #3 chi- 
mera, containing the/~l cytoplasmic domain, was constructed by first gen- 
erating an EcoRl site at bases 2387-2392  of/~  eDNA sequence. After 
HindlII digestion, a 400-bp fragment containing the complete #1 cytoplas- 
mic domain and partial 3' non-coding sequences was isolated and subcloned 
into the HindlH site of  CDMS. This construct was then digested with EcoRl 
and ligated with a 2.2-kb EeoRI fragment from CD3a (68)  containing its 
transmembrane and extracellniar domains./~2 cytoplasmic sequences were 
first isolated by the PCR from a B2 eDNA, and then subcloned into the 
MluI and XhoI sites of CDMS.  The B2 cytoplasmic domain chimera was 
then generated by digestion with MluI and HindlIl and ligation with a corre- 
sponding MluI-HindlIl fragment from CD3a containing its extraceUular 
and transmernbrane sequences. Chimeric a  subunits were generated using 
a previously described strategy (69). Cytoplasmic sequences from t~v, c~, 
aL, a2, ot6A, and a~B were isolated from the appropriate eDNA clones by 
PCR (57).  Amplified products were digested with HindIII and XbaI and 
subcloned into HindlII and Xbal cut CDMS. After digesting with HindlH, 
these constructs were ligated with a HindIll fragment from CD2b (68) con- 
talning its extracellular and transmembrane domains. PCR oligonucleotides 
for aLA were designed to omit the VGFFK sequence. Its construction fol- 
lowed the procedure for other a  chimeras. The a~ variant was made by 
first generating a SalI site in CD2b coding sequences corresponding  to bases 
3061-3066.  This vector was then digested with SalI and XbaI and ligated 
to a Sall-Xbal Blueseript vector sequence (bases 674-731). All constructs 
were verified by DNA sequencing and purified by CsCI centrifugation be- 
fore transfection. Oligonucleotides were synthesized on a model 391 DNA 
Synthesizer (Appl. Biosystems Inc., Foster City, CA). 
Ligand Binding 
The binding of 125I-Fg or t25I-Fn to cultured cells was accomplished as de- 
scribed (26, 67). Cells were harvested with EDTA and trypsin as described 
above for flow cytometry and resuspended in a modified  Tyrode's buffer (150 
raM NaCI, 2.5 mM KCI, 2 mM NaHCO3, 2 mM MgCl2, 2 mM CaCl2, 
1 rag/m/BSA, and 1 rag/m/dextrose). A typical assay included 120 #1 of 
ceils  (2 X  I06  ceils  per  tube),  40/~I  of  radiolaboled  protein,  and  40/zl  of 
inhibitor  (GRGDSP peptide,  blocking  antibodies)  or  agonist  (activating  an- 
tibody).  After  30 rain  at  room temperature,  50-~I  aliquots  were layered  in 
triplicate  on  0.3  ml  of  20% sucrose  and  centrifuged  for  3  m/n  at  12,000  rpm. 
125I-labeled protein associated with the cell  pellet was determined by scin- 
tillation spectrometry. Nonsaturable binding was determined in the pres- 
ence of 2  mM GRGDSP peptide. Data were fit to equilibrium binding 
models by the nonlinear least squares curve-fitting LIGAND program (64). 
In binding experiments using metabolic inhibitors, the cells were first in- 
cubated with 2 rag/m/2-deoxyglucose and 0.1% sodium azide for 30 rain 
at room temperature before addition of radiolabeled ligand. In washout ex- 
periments, cells treated in this way were washed, incubated with Tyrode's 
containing 1 rag/m/dextrose for 30 min at room temperature, and then ana- 
lyzed for ligand binding. 
lmmunoprecipitation 
Transfectants were surface labeled by the Iodogen method according to the 
manufacturer's instructions (Pierce Chem. Co., Rockford, IL) and solubi- 
lized in lysis buffer (10 mM Hepes (pH 7.5),  0.15 M NaC1, 50 mM octyl- 
glucoside, 1 mM CaCI2,  1 mM MgCI2,  1 mM phenylmethylsulfonyl fluo- 
ride, 0.I mM leupeptin, and 10 mM N-ethylmaieimide). Cell extracts were 
immunoprecipitated with polyelonal antiserum directed against the a~ or 
c~5 cytoplasmic domains and a  monoclonal antibody against the am~3 
complex (2G12).  The antibodies were attached onto preswollen protein 
A-Sepharose beads (Pharmacia LKB Bioteelmology Inc., Piscataway,  NJ) 
by incubation at 4°C overnight. The antibody-conjugated Sepharose beads 
were washed, pelleted by centrifugation, and then incubated with the deter- 
gent lysates from the surface labeled cells overnight with shaking.  The 
Sepharose beads were washed extensively in lysis buffer,  resuspended in 
sample buffer (53), and boiled for 5 min. After centrifugatlon, the precipi- 
tated protein was resolved by SDS-PAGE (non-reducing, Z5 % acrylamide 
gels). Gels were dried, and radiolabeled polypeptides were visualized by 
autoradiography. 
Polymerase Chain Reaction 
Total  RNA was isolated from 106 transfected cells using the RNAzol re- 
gent (Cirma Biotecx). First strand eDNA synthesis from 5 ~g of RNA was 
performed with the eDNA cycle kit (Invitrogan) using oligo dT as a primer. 
Coding  sequences downstream of the am  transmembrane region were 
specifically amplified with a  5' primer specific for transmembrane ctm 
(2bsf: CGGGCC~GGAGA~CATTC)  and 3'primers specific for 
the cytoplasmic sequences of otab (aabcyt:  CTCTGI~oC_d3A~- 
CGA) and cx5 a~cyt: TGTAAACAAGC~TCCTTCAC). Amplified products 
were analyzed by agarose gel electrophoresis. 
Results 
Cell l)~e-Specific and Enemy-dependent Affinity 
Modulation of lntegrin aJB~ 
As noted above, there is evidence for cell type-specific con- 
trol of the adhesive function of integrins.  To begin to inves- 
tigate the cell type-specific control of ligand-binding affinity, 
we first analyzed the binding of soluble Fn to cells expressing 
integrin o~5~. The cells analyzed fell into two groups: those 
that bound Fn with only low affinity (Kd >1/~M), e.g., K562, 
THP1,  U937, and peripheral  blood T  cells, and those that 
bound with moderate affinity (Kd ",,100  nM),  e.g.,  CHO, 
WI-38, and MG63 cells (Fig.  1 A).  The low affinity o~/~1 
was intrinsically functional since it bound Fn after activation 
with the 8A2 monoclonal antibody (26) (Fig.  1 A) and was 
expressed at comparable levels to high affinity CtsB~ (Fig.  1 
B).  Specificity  of Fn  binding  to  high  affinity  as/~t was 
verified by inhibition with an anti c~5 antibody (Fig.  1 A). 
To find out whether spomaneous high affinity Fn binding 
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Figure L The high affinity  state of as/~ is cell type-specific and 
energy-dependent.  (.4) t25I-Fn (50  nM)  was incubated  at 22°C 
with CHO or K562 cells. After 30 min, bound Fn was assessed by 
centrifugation through a sucrose cushion as described in Materials 
and Methods.  ,sB~-specific binding was established by blocking 
binding to the CHO cells with PB1, an anti-hamster ~'s. Binding to 
K562 cells was induced by addition of 20 nM activating antibody 
(842) and was inhibited by the anti-as, BIIG2. (B) The level of 
surface expression of asfl~ in the two cell types. CHO and K562 
cells were stained with irrelevant mouse IgG (dotted line), an anti- 
/3~ antibody (K562:SA2, CHO:7E2) (solid line), or an anti-o~5 anti- 
body (K562:BIIG2, CHO:PB1) (dashedline), and then analyzed by 
flow cytometry as described in Materials and Methods.  (C) The 
binding of ~25I-Fn to CHO cells (Resting), to cells incubated in 
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Figure 2. Amino acid sequences of wild-type and variant integrin 
cytoplasmic domains. Single letter amino acid code is used. The 
arrows underneath the am (residue 990) and B3 (residue 727)  se- 
quences  denote the position at which chimeric cytoplasmic do- 
mains were joined to the extracellular and transmembrane domains 
of ~o and ~3. The position of stop codons producing cytoplasmic 
truncations are noted by triangles, while the $752"~P point muta- 
tion in/~3 is indicated. The residues deleted in the at.A cytoplas- 
mic domain are overlain by the heavy line. 
to o~5fll is an active process,  we treated CHO cells with a 
combination of inhibitors of oxidative phosphorylation (NaN3) 
and anaerobic glycolysis (2-deoxyglucose).  This resulted in 
loss of specific high affinity Fn binding. This effect was par- 
tially reversible since washout of the metabolic inhibitors re- 
sulted in restoration of 75 % of the high-affinity binding (Fig. 
1 C).  Thus, high affinity Fn binding to integrin as#, is cell 
type-specific and an active cellular process. 
The Cytoplasmic Domains of a~  Confer an 
Energy-dependent High Affinity State on Olr~fl~  in 
Some Cells but Not Others 
To decide  whether  the  cytoplasmic domains  of olsB~ were 
involved in cell type-specific affinity modulation, we gener- 
ated chimeras in which the cytoplasmic domains of Otnb and 
t3 were replaced with the corresponding sequences from o~5 
and fl~ (Fig.  2).  The ot and fl chimeras were then cotrans- 
fected into CHO or K562 cells, and the affinity state of the 
extraceUular  a~3  reporter  group was assayed by binding 
of PAC1,  an antibody specific for the high affinity state of 
ot~3  (81).  The double  chimera  bound  PAC1  when  it was 
expressed  in  CHO  cells  (Fig.  3).  Since  wild-type  o~/33 
does not bind PAC1 when expressed in CHO cells (67), it is 
concluded that the Otsfl, cytoplasmic domains conferred the 
high affinity state on O~nbfl3. In sharp contrast, PAC1 did not 
bind to the double chimera in K562 cells.  However,  PAC1 
medium containing 2 mM deoxyglucose and 0.1% sodium azide 
(DOG/Az), or to ceils washed free of these inhibitors and returned 
to  glucose-containing  medium (Wash +  Glc) was determined. 
Specificity of binding  to ~,fll was verified by inhibition with the 
PB1 antibody. 
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affinity states. (A) FACS analysis. CHO or K562 cells were stably 
transfected with the chimeras containing the cytoplasmic domains 
of ~5 and/~l and the affinity state of the C~nb/~3 extracellular domain 
was assayed by its ability to bind PAC1 in the absence (solid line) 
or presence (dotted line) of 1 mM GRGDSP. Depicted are flow 
cytometry histograms. The K562 transfectants specifically bound 
PAC1 only after incubation with 6 ttM activating antibody, anti- 
LIBS 6. (B) lmmunoprecipitation analysis of K562 transfectants. 
Wild-type K562 cells (None) or stable transfectants expressing the 
c~ subunit noted (air,  as  =  c~5 cytoplasmic domain chimera) were 
surface iodinated, lysed, and immunoprecipitated with polyclonal 
antibodies specific for the or5 and Ol,b  cytoplasmic domains or with 
a monoclonal antibody reactive with the extracellular domain of 
tXnb/33 (2G12). Immunoprecipitates were resolved by SDS-PAGE 
and constituent polypeptides were visualized by autoradiography. 
(C) Reverse transcdptase-polymerase  chain reaction (RT-PCR). 
The location of the 2bsf, 2bcyt and c~scyt  primers used for PCR 
bound after addition of an activating antibody, anti-LIBS6, 
confirming that the ligand-binding site was intact (Fig. 3 A). 
Thus, the capacity of cell type-specific elements to modulate 
affinity depends on the integrin cytoplasmic domains. 
Since K562 cells express endogenous O~b under certain 
conditions (12), it was necessary to verify that all of the a~ 
expressed in the ~  chimera transfectants contained the 0~5 
cytoplasmic  domain.  Immunoprecipitation  of c~  chimera 
transfectants with an anti-as cytoplasmic domain antibody 
isolated polypeptides corresponding to transfected ~x~o and 
/33 chimeras and endogenous o~5/3t (Fig.  3 B). In contrast, 
an anti-ol~ cytoplasmic domain antibody immunoprecipi- 
tated no labeled polypeptides. An anti-cx5 cytoplasmic anti- 
body  precipitated  only  endogenous  oe5/3~ from  wild-type 
ol~3 transfectants. In addition, we confirmed fidelity of ex- 
pression at the mRNA level. Reverse transcriptase PCR was 
performed using a 5' primer specific for the extracellular do- 
main  of O~b  and  3' primers  specific for cytoplasmic do- 
mains of Olnb or 0~5 (Fig. 3 C). A specific 393-bp band was 
observed from c~ chimera transfectants when primed with the 
3' or5 oligonucleotide. A specific 294-bp band was observed 
with wild-type otnb transfectants when primed with the 3' 
ot~ oligonucleotide. No bands  were observed when inap- 
propriate 3' primers were used. 
As was shown in Fig.  1, high affinity Fn binding to ct5/31 
depends on active cellular metabolism.  We therefore ana- 
lyzed the effects of NaN3 and 2-deoxyglucose on the affinity 
state of the double chimera in CHO cells. These inhibitors 
blocked both PAC1 (Fig.  4 A) and Fg (Fig.  4  B) binding. 
Anti-LIBS2,  an  activating  antibody  (29),  restored  high 
affinity binding.  Furthermore, the metabolic blockade was 
reversible since high affinity ligand binding reappeared after 
the inhibitors were washed out (Fig. 4 A). These results show 
that c~5/3t cytoplasmic sequences confer a ceil type-specific, 
energy-dependent, high affinity state on the extracellular do- 
main of a.b/~3. 
Both ~ and {3 Cytoplasmic Domains Are Involved in 
Affinity Modulation 
To  learn  which  cytoplasmic  domain  specified  the  high 
affinity state in CHO cells, we transfected each subunit chi- 
mera with a  complementary wild-type subunit.  Transfec- 
tants expressing both ol and/3 chimeras or expressing the chi- 
meric o~ but wild-type/33 subunits bound PAC1 (Fig. 5 A). 
In contrast, cells expressing the 13 chimera with wild-type 
Ol~b were in a low affinity state and bound PAC1 only after 
addition of anti-LIBS2 (Fig. 5 A). These results show that 
a  cytoplasmic sequences are involved in specifying affinity 
state. 
To find out if the/3 subunit was also involved in specifying 
the high affinity state in CHO cells, we constructed two/33 
analysis are illustrated. The transmembrane (TM: crosshatched), 
3' untranslated (3'UZ: stippled), and cytoplasmic and extracellular 
domain (clear) sequences are indicated. RT-PCR  was performed as 
described in Materials and Methods with the 5' 2bsf primer and 3' 
primers specific for ¢xn~ or c~s 3' untranslated sequences. Amplified 
products were analyzed by agarose gel electrophoresis (below) with 
arrows denoting the position of  the 393 and 294 bp bands. Transfec- 
rant type is listed above while the 3' primer used is noted below. 
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Figure 4. The high affinity state of the c~5 cytoplasmic domain chi- 
mera is energy-dependent. (A) PAC1 binding. Stable CHO transfec- 
tants expressing the u5 and 3~ cytoplasmic domain chimeras were 
assayed for PAC1 binding in the absence (solid line) and presence 
(dotted line) of 2 mM GRGDSP by flow cytometry. Transfectants 
incubated with 2 mg/ml deoxyglucose and 0.1% NaN3 (Inhibitors) 
as described in Materials and Methods manifested loss of specific 
binding. Addition of 6/~M anti-LIBS2 (lnhibitors + Anti-LIBS2) 
or washout of these inhibitors (lnhibitors + Washout) and return 
to glucose-containing medium reconstituted specific PAC1 binding. 
(B) Fibrinogen binding. Stable CHO transfectants expressing the 
cytoplasmic domains noted below were analyzed for fg binding as 
described in Materials and Methods. Constitutive binding to trans- 
fectants expressing the c~5 chimera with wild-type/33 was inhibited 
by 2 mg/ml deoxyglucose plus 0.1% NAN3; binding to transfec- 
tants expressing the ~',b~991 or at.& variant was not (see below). 
cytoplasmic variants, 33A724  and 33(S752"*'P).  The former 
is  a  truncation mutant that ends  at  D 723, while the  latter 
contains a single nucleotide alteration resulting in a Set  752-'* 
Pro substitution (Fig. 2). These B3 cytoplasmic domain mu- 
tants were then cotransfected with the o~ chimera. In contrast 
to wild-type B3, coexpression of either 33 variant with chi- 
meric ~ resulted in a receptor that failed to bind PAC1 con- 
stitutively (Fig. 5 B). Thus, the cytoplasmic domain of the 
3  subunit as well as the el subunit is  involved in affinity 
modulation. 
Regulation of  lntegrin A~nity by the a Subunit 
Cytoplasmic Domain Is cx Subunit-Specific 
These data established that the cytoplasmic domains of O~.b 
and c~5 specify different affinity states in CHO cells; ~,b the 
low and c~5 the high affinity state.  To learn whether there 
are  consensus  activation  sequences,  we  constructed  chi- 
meras  with  the  cytoplasmic domains  of six  additional  o~ 
subunits and analyzed their affinity state after cotransfection 
with  33  into  CHO  ceils.  The a  cytoplasmic domains  of 
three other 3~  family members  (at2, c~6A, ct6B) conferred 
PAC1 binding (Fig. 6 a), while those chimeras containing a 
subunit cytoplasmic domains  from 32  (arM, OtL) (data not 
shown) or 33(cry) (Fig. 6 A) families did not. The same re- 
sult was obtained with the 3 chimeras containing cytoplas- 
mic domains of the relevant 3  subunit partner (3,  for ct2, 
c~v, a6A,  and ot6B or 32 for O~L and c~M). Similar to the or5 
chimera, constitutive PAC1 binding was also dependent upon 
the/5 cytoplasmic domain. It was lost when the ct2, ct6A, or 
ot~B chimeras were cotransfected with 33A724 or 33S752P 
(Fig. 6 B). Thus, the a  subunit cytoplasmic domain desig- 
nates integrin-specific affinity differences. The 3 subunit cy- 
toplasmic domain may be permissive for the high affinity 
state. 
Deletion of Conserved ~ Cytoplasmic Sequences 
Results in High A~inity Ligand Binding 
That Is Independent of  Metabolic Energy and 
the (3 Subunit Cytoplasmic Domain 
We previously reported that constitutive ligand binding to 
Crab33 results from a truncation of the cytoplasmic domain 
of arab (69). To identify the important deleted ctt~ cytoplas- 
mic residues, we generated additional variants. Integrin t~ 
subunit  cytoplasmic domains  contain a  highly  conserved 
GFFKR sequence at their NH2 termini (Fig. 2). As previ- 
ously reported (69, 97), the o~abA991 truncation eliminates 
this motif and results in constitutive PAC1 binding (Fig 7 A; 
panel A) whereas a truncation after the GFFKR (CtnbA996) 
does not (Fig. 7 A; panel C). This pinpoints the conserved 
motif as a regulator of integrin affinity. To test this idea, we 
removed the LGFFK residues from the cytoplasmic domain 
of an ell cytoplasmic domain chimera (Fig.  2).  This chi- 
mera was selected because it possesses the longest o~ cyto- 
plasmic domain. Coexpression of this chimeric internal de- 
letion mutant (actS)  in CHO cells with 33 resulted in high 
affinity PAC1 binding (Fig. 7 B, panel A). Finally, to further 
exclude contributions from downstream ¢x sequences,  we 
generated a variant that contains a 24-residue random cyto- 
plasmic  sequence (Fig  2).  This construct (O~R.) alSO con- 
ferred high affinity binding when expressed in CHO cells 
with wild-type 33 (Fig. 7 A; panel B). 
To gain insight into the mechanisms of high affinity bind- 
ing conferred by the GFFKR deletion mutants, we examined 
the requirements for cellular metabolism and 3 cytoplasmic 
sequences. In contrast to the constitutively active chimeras, 
high affinity PAC1 binding in the GFFKR deletion variants 
was maintained when they were coexpressed with the trun- 
cated 33 subunit (Fig.  7 B; panel B).  In addition,  in con- 
trast  to  transfectants  expressing  constitutively  active  ¢x 
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Figure 5. Role of  both t~ and B 
cytoplasmic  domains  in  af- 
finity modulation.  (.4) The c~ 
subunit  cytoplasmic  domain 
specifies  affinity  state.  CHO 
cells  were  transiently  trans- 
feeted  with  subunits  com- 
prised of the extracellniar  and 
transmembrane  domains  of 
am and 53 joined to the indi- 
cated  cytoplasmic  domains. 
The  affinity  state  of the  ex- 
traeellular  portion  of  txmB3 
was  assessed  by PAC1 bind- 
rag.  Binding  was  analyzed 
in  the  absence  (solid  line) 
or  presence  (dotted  line) 
of GRGDSP peptide.  Histo- 
grams of  cells incubated in the 
presence of 6/~M anti-LIBS2 
are  depicted  in  the  lower 
panels.  Specific PAC1 binding 
is present in both transfectants 
containing the a5 cytoplasmic 
domain  irrespective  of  the 
presence of either the/53 or/~l 
cytoplasmic domain on the/~3 
subunit.  In  contrast,  PAC1 
specifically  bound  to  those 
transfectants  containing  the 
c~nb cytoplasmic domain only 
in the presence of the activat- 
ing antibody, anti-LIBS2. (B) 
Affinity  state  is  dependent 
upon the /~3 cytoplasmic do- 
main.  Stable  CHO cell lines 
expressing recombinant t~m~3 
chimeras containing the noted 
cytoplasmic  domains  were 
reacted with PAC1 and bound 
antibody was detected by flow 
cytometry  as  described  in 
Materials  and Methods.  Bind- 
ing was analyzed in the ab- 
sence (solid line) or presence 
(dotted line) of  GRGDSP pep- 
tide. The intrinsic  functional- 
ity of each construct was as- 
sessed by PAC1 binding in the 
presence of 6/~M anti-LIBS2 
(lower  panels).  A  ~3  cyto- 
plasmic  truncation  (A724) 
and single amino acid substi- 
tution(S752~p)  both  abol- 
ished  the  constitutive  high 
affinity state  conferred by the 
cytoplasmic domain of ets. 
chimeras, transfectants expressing the GFFKR deletions re- 
tained high affinity for Fg (Fig.  4 B) and PAC1  (Fig. 7 B; 
panel C) when treated with the metabolic inhibitors NaN3 
and  2-deoxyglucose.  Finally,  the  OtLA mutant  conferred 
cell-type independent activation, since it was active in K562 
(Fig,  7 B; panel D) and COS (not shown) as well as CHO 
cells. Thus, deletions in the highly conserved GFFKR motif 
resulted in a cell type-independent high affinity state that was 
resistant  to  metabolic  inhibitors  and  truncation  of the  /3 
subunit. 
Discussion 
The major findings of this work are (a) the affinity state  of 
integrin ot~Bt is regulated by cell type-specific factors.  The 
high affinity state requires active cellular processes suggest- 
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(A) Effect of different tx cytoplasmic domains. Chimeric c~ subunits 
consisting of extracellular and transmembrane c~n~ with the indi- 
cated cytoplasmic domain were transiently cotransfected with/33 
into CHO cells. PAC1 binding was quantified by flow cytometry and 
the  activation index was  calculated as:  100*(Fo-FR)/FR  where: 
Fo  =  Mean Fluorescence Intensity in the absence of inhibitor; 
FR  =  Mean  Fluorescence Intensity  in  the  presence of 2  mM 
GRGDSP. Depicted are the mean +  SD of at least three independent 
experiments for each ~x chimera. (B)/3 Subunit cytoplasmic  domain 
dependence of the high affinity state, tx Subunit chimeras contain- 
ing the indicated cytoplasmic sequences were cotransfected with a 
/33  subunit whose cytoplasmic domain was truncated (f13A724), 
contained the $752~P mutation ($752P),  or had been exchanged 
for the homologous region of/3~.  PAC1 binding was analyzed as 
described in panel A. Mean 4- SD of at least three independent ex- 
periments for each c¢/3 pair. 
ing that low affinity may be the default state. (b) Cell type- 
specific  signals  that modulate integrin affinity are  trans- 
mired through the cytoplasmic domains. Both cytoplasmic 
domains are involved in these signaling events.  (c) Certain 
deletions in the conserved GFFKR sequence in the c~ subunit 
cytoplasmic domain reset the default state to high affinity. In 
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Figure 7. GFFKR deletion variants confer an energy and/3 subunit 
cytoplasmic domain-independent high affinity state. (.4) GFFKR 
sequence deletion activates c~/33. Stable CHO cell lines were es- 
tablished by cotransfection of c~nb containing the noted c~ cytoplas- 
mic domain with wild-type/33. PAC1 binding in the absence (solid 
line) and presence (dotted line) of GRGDSP was assessed by flow 
cytometry.  The  ,,m,  A991  transfectant,  which  lacks  GFFKR, 
specifically  binds PAC1 (panel A). In contrast, the <xm,A996 trans- 
fectant,  which retains GFFKR, binds only after activation with 
anti-LIBS2 (panels C and D). P-_cplacement  of the ce~ cytoplasmic 
domain with random sequence also induces PAC1 binding (panel 
B, av.,). (B) Energy,/3 subunit cytoplasmic domain, and cell type- 
independent high affinity state of GFFKR deletion variants. CHO 
cells were transiently transfccted with chimeras of the extracellnlar 
and transmembrane domains of Ctnb/33  joined to the indicated cyto- 
plasmic domains. Specific PAC1 binding to the population of cells 
expressing cxnb/33 was detected as described in Fig. 7 A. A GFFKR 
"loop out" mutant manifested PAC1 binding (panel A) that was 
maintained in the presence of 0.1% NaN3 and 2 mM 2-deoxyglu- 
case (panel  C).  This  treatment abolished ligand binding to an 
ctm,/33  chimera  bearing  the  cytoplasmic  domain  of  c~5/31 (not 
shown, but of. Fig. 4 A). High affinity state was also maintained 
despite an extensive deletion of the/33 cytoplasmic domain (panel 
B) that disrupted PAC1 binding to the as/3~ chimera (not shown 
but cf. Fig. 5 B). Similar results were obtained with tx~oA991 and 
cth transfeetants. A stable K562 cell line bearing the GFFKR de- 
letion mutant specifically  bound PAC1 (panel D), but the c~s/3~ chi- 
mera was not active in these cells (cf. Fig. 3 A). 
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~3  ~3A724  ~3S752P  81  ~2 
~I/b  LO  LO  LO  LO  - 
or2  HI  LO  LO  HI  - 
aS  HI  LO  LO  HI  - 
ct6A  HI  LO  LO  HI  - 
.6B  HI  LO  LO  HI  - 
~L  LO  -  -  -  LO 
c~M  LO  -  -  -  LO 
~v  LO  .... 
Summary of the affinity states, as assayed by PAC1 binding to CHO ceils transiently transfected with chimeras of the extraceUular and transmembrane domains 
of c~n~ joined to the indicated cytoplasmic domains.  Affinity states were defined as HI =  Activation Index ;~60 and LO =  Activation Index ~45.  Double 
underlining indicates the experiments that establish the importance of the ~ subunit cytoplasmic domain in maintenance of the high affinity state. In all instances 
of the high affinity state, treatment with NaN3 and 2-deoxyglucose resulted in reversion to the low affinity state. 
these deletion mutants, the high affinity state is independent 
of cell type, and is not blocked by metabolic inhibitors or by 
near complete truncation of the/3 subunit tail. These studies 
show that the cytoplasmic domains of integrins control their 
affinity state. Thus, these domains become attractive targets 
for approaches to alter cell adhesion. Further, the conserved 
GFFKR motif of the u  subunit cytoplasmic domain main- 
tains the default low affinity of the extracellular domain. 
The ligand-binding affinity of integrin c~5/~ depends on 
the cell type in which it is found. Such differences in ligand- 
binding affinity could well account for previous reports of 
cellular variation in the adhesive function of integrins 0, 15, 
25,  35,  49,  55,  62,  66,  94).  It is possible that cell type- 
dependent affinity  differences are due to structural variations 
in ots#~ synthesized in the different cell types. Permanent 
structural variants (e.g., alternative splicing [5,  11, 41, 42, 
92], alternative proteolytic processing [58]) can be excluded 
as the sole cause of the affinity differences reported here be- 
cause the affinity of o~5#~ was reversibly decreased by meta- 
bolic  inhibitors.  Consequently,  the  increased  affinity of 
c~5/~ in CHO cells seems the result of active cellular sig- 
nais. Since the metabolic inhibitors caused the reversion of 
oc5/~ to the low affinity state, it seems that low affinity is the 
default state of ~5/3~. Similarly o~n~/33 and ~./~2 usually re- 
quire active cellular processes for high affinity ligand bind- 
ing (4, 61). Furthermore, purified c~trd33 in liposomes spon- 
taneously reverts to low affinity after removal of activating 
ligands (84). Thus, default low affinity state may be a general 
property of integrins. 
Signals that modulate the  affinity of o~5/~t are  targeted 
through the integrin's cytoplasmic domains. Joining the cyto- 
plasmic domains of ~/3~ onto the extracellular and trans- 
membrane domains of O~zrd~3, an  exchange involving less 
than 5 % of the total mass of the integrin, caused the o~n~/~3 
to assume the high affinity state in CHO cells. Biologically 
relevant signals mediated the increased affinity of the chi- 
mera since: (a) it was cell-type specific, (b) it could be reset 
to the default low affinity by addition of inhibitors of oxida- 
tive phosphorylation and anaerobic glycolysis, and (c) a B3 
cytoplasmic domain mutation ($752--'P) returned the  chi- 
meric integrin to the low affinity state. This naturally occur- 
ring  mutation  is  associated  with  defective  activation  of 
o~mfl3 in platelets (16). Cell-type specific signaling elements 
that interact with the integrin cytoplasmic domains could 
readily explain the distinctive cellular influences on integrin 
affinity. In view of the marked sequence divergence of the ¢x 
subunit tails (Fig.  2),  multiple such integrin-specific ele- 
ments might exist. 
As summarized in Table I, the a  subunit cytoplasmic do- 
main designated integrin-specific  differences in affinity state. 
In  CHO  cells,  ors, ot~A and  B,  and  o~2  cytoplasmic tail 
chimeras  specified  the  high  affinity state.  The  ot~,A996 
truncation mutant leaves the common (Fig. 2) KXGFFKR 
motif  and results in a low affinity state. This suggests that ac- 
tivation signaling sequences important for conversion of the 
integrin to a  high affinity state reside carboxyterminal of 
GFFICR in as, ot6A and B, and a2. Thus, deletion of related 
sequences could account for the reduction of cell adhesion 
by certain truncations of the a4 (45) or o~2 (46) cytoplasmic 
tail.  In  addition,  truncations  of  O~nb or  o~  that  retain 
GFFKR lose the capacity to constrain integrin localization 
to focal adhesions (9, 97). This result suggests the existence 
of elements within the carboxyl terminal portion of the ot 
subunit that inhibit targeting of the integrin to focal adhe- 
sions.  In CHO  cells,  the  full-length O~nb cytoplasmic do- 
main specifies a low affinity state but still constrains the lo- 
calization of ~b/~3 to focal adhesions. Thus, we suspect that 
the o~ cytoplasmic domain elements that control targeting to 
focal adhesions and ligand-binding affinity are not identical. 
These elements may also be involved in the role of c~ subunit 
cytoplasmic domains in more complex cellular functions 
such as collagen gel contraction, cell migration, and cell 
adhesion (14, 45, 46). 
The cytoplasmic domains of either/3~ or/33 were required 
for the activation of the ot subunit chimeras. Moreover, the 
capacity of #3($752---P) to  disrupt activation, underscores 
the specificity of the B subunit requirement. Interestingly, 
/~3 Ser  TM  is homologous to a  Thr (Fig.  2)  involved in the 
adhesive function of art2 (38).  S  752 is not extensively phos- 
phorylated in  platelets  (40).  We have  found no obvious 
difference in the phosphorylation of as cytoplasmic domain 
chimeras in CHO cells and K562 cells (unpublished results). 
Thus, the mechanism of the effect of the $752--*P mutation 
on inside-out signaling remains to be resolved. 
Mutations that delete portions of the conserved GFFKR 
sequence appear  to reset c~m~3 to  a  default high affinity 
state. As summarized in Table II, a truncation mutant that 
removes this  sequence  (OtnbA991) is  constitutively active, 
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Domain:  Hinge Mutants 
83  ~3A  724  ~3S752P 
edlb  LO  LO  LO 
odlbA991  HI*  HI  HI 
odlbA996  LO*  LO  LO 
c~LA  HI*  HI  HI 
LO*  -  - 
c~Ra  HI*  HI  HI 
Summary of the affinity  states  of  the extracellular  domains of am~3 when 
joined  to  the  indicated  cytoplasmic  domains  and  transiently  expressed  in  CHO 
cells  as assayed by PACI  binding.  Affinity  states  were defined  as HI  = 
Activation  Index )60 and  LO = Activation  Index ~45. Asterisks  indicate  the 
experiments  establishing  the  role  of  the  GFFKR  motif  in  maintenance of  the 
low affinity  state.  Double underlining  indicates  the  experiments  that  establish 
the  lack  of  importance  of  the  ~ subunit  cytoplasmic  domain in  supporting  the 
high affinity  state  in  these  mutants.  In  all  instances  of  the  high affinity  state, 
treatment  with NaN3 and 2-deoxyglucose did not result  in reversion  to the 
low affinity  state. 
whereas a  truncation that retains this sequence  (ot~,A996) 
remains inactive. Moreover, a KLGFF loop out mutation in 
the ~L cytoplasmic domain or replacement of the  c~ cyto- 
plasmic domain  with  a  24-residue  random  sequence  also 
resulted in high affinity Fg and PAC1 binding. The nature of 
the  high  affinity  state  in  these  GFFKR mutants  differed 
markedly from that  in  the  cytoplasmic domain chimeras. 
Specifically, the deletions resulted in default high affinity in 
all cells tested. In addition, high affinity was maintained de- 
spite addition of metabolic inhibitors and truncation of the 
13 cytoplasmic domain. Of note in this context, a truncated 
o~5, lacking GFFKR,  is more efficient at assembling a  Fn 
matrix than wild-type e¢5 (96).  This effect could be due to 
increased Fn binding,  since matrix assembly may be regu- 
lated  by  the  affinity  state  of o~5/31 (26).  The  GFFKR  se- 
quence probably resides in the cell interior because there are 
generally  about  20  hydrophobic  residues  preceding  the 
charged Lys of the KXGFFKR motif (6,  18,  19, 54, 72,  83, 
88-91). Mutations of intramembrane or cytoplasmic (13, 56, 
73) residues can lead to constitutive transmembrane confor- 
mational changes in  other receptors.  In integrins,  certain 
cytoplasmic domain mutations also initiate such a constitu- 
tive transmembrane alteration. 
The high affinity state of otmg3 provoked by deletion of 
GFFKR suggests possible mechanisms for transmembrane 
signaling  through  integrins.  Transmembrane  domains  of 
type I membrane proteins such as integrin ot and/3 subunits 
are presumably constrained into helices (83). Consequently, 
transmission of con~rmafional information across the mem- 
brane probably involves changes in the spatial relationships 
of the ot and/5 subunits. The bacterial aspartate receptor, like 
integrins  (63),  has ligand  contact  sites in  each of its  two 
Figure 8.  Working hypotheti- 
cal model of affinity modula- 
tion of integrins. Depicted is a 
schematic that accommodates 
the results reported here. Cell- 
type  specific  energy-depen- 
dent cytoplasmic  signals tar- 
get  the  integrin  cytoplasmic 
domains. The unidentified fac- 
tor(s) responsible for these sig- 
nals  (represented  as lntegrin 
Actimtor  Complex) interacts 
with the cytoplasmic domains 
to provoke changes in the spa- 
tial relationships or conforma- 
tions of the c~ and ~  subunit 
cytoplasmic  tails. Such changes 
then  traverse the  membrane- 
proximal GFFKR sequence to 
alter the relationship of a  and 
/3 subunit transmembrane do- 
mains and ultimately the con- 
formation of the extraceUular 
domain.  Although  the  ac- 
tion is depicted as a scissors, 
other motions such as pistons, 
seesaws, or rotation  (47, 87) 
of the  subunits are also pos- 
sible.  Since  these  motions 
must traverse GFFKR to reach 
the transmembrane  domains, 
GFFKR could be vi~,ved as a 
component of  a hinge that con- 
nects  the  cytoplasmic  and 
the  transmembrane  domains. 
Thus,  deletions  in  GFFIGR lock 
the integrin hinge in an irre- 
versible high affinity state: 
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]~ shift of membrane-adjacent helices relative to each other. 
This shift may result in outside-in signaling. In integrins, the 
cytoplasmic  GFFKR  sequence  could  regulate  the  spatial 
relationships  of the ot and/3  subunits through interactions 
with the j3 subunit resulting in inside-out signaling. Alterna- 
tively,  GFFKR could bind membrane lipids and perturba- 
tions of such interactions could explain lipid modulation of 
integrin function (17, 37, 84). Finally, cytoplasmic proteins 
could bind to this sequence.  Calreticulin,  a protein usually 
thought to reside  in the endoplasmic  reticulurn,  has been 
reported  to  bind  to  a  short  synthetic  peptide  containing 
GFFKR  (74).  If this association  occurs in vivo,  then the 
calreticulin-GFFKR  interaction  or one like  it may  set the 
integrin's  default affinity  state.  A  search  of the  Swissprot 
Database, using Wordsearch (21), identified the GFFKR se- 
quence in several C4 zinc finger ("steroid fingers  n) transcrip- 
tion factors  (e.g.,  retinoic  acid receptor  [60],  Drosophila 
tailless  [70],  Nur/77  [76]).  The  sequence  is  in  the  most 
highly  conserved site in this receptor  family (27,  77,  78). 
Moreover, in the glucocorticoid receptor, this region forms 
part of an alpha helix that is initiated by two zinc-coordinat- 
ing cysteines (59). This helix forms contacts with DNA that 
are critical for activity (27, 59, 77). In integrins, KXGFFKR 
presumably adjoins an c~ helix. By analogy with the steroid 
fingers,  GFFKR may therefore possess ot helical  structure 
and participate in functionally important interactions. 
The data presented here suggest a working hypothesis for 
affinity modulation of integrins (Fig.  8).  Cell-type  specific 
and energy-dependent cytoplasmic signals target the integrin 
cytoplasmic domains. The unidentified factor(s) responsible 
for these signals (represented as IAC in Fig.  8) require the 
presence of elements of both cytoplasmic domains. The IAC- 
cytoplasmic domain interaction could provide changes in the 
spatial relationships or conformations of the c~ and/3 subunit 
cytoplasmic tails.  Such changes then probably traverse the 
membrane-proximal GFFKR sequence to influence the rela- 
tionship of o~ and/3 subunit transmembrane domains and ulti- 
mately  the conformation  of the extracellular  domain.  Al- 
though the action is depicted as a %cissors" in Fig.  8, other 
motions such as "pistons; "seesaws; or rotation (47, 87) of 
the  subunits are  also  possible.  Since  these  motions  must 
traverse  GFFKR  to  reach  the  transmembrane  domains, 
GFFKR could be viewed as a component of a "hinge" that 
connects the cytoplasmic and the transmembrane domains. 
Thus, deletions in GFFKR might lock the integrin hinge in 
an irreversible high affinity state (Fig.  8).  In theory, other 
mutations might lock the hinge in a low affinity  state. 
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